Seattle Genetics Initial Results in Metastatic Colorectal Cancer Trial

-First Presentation of Tucatinib With Trastuzumab in Metastatic Colorectal Cancer –

– Findings Presented Today at the European Society for Medical Oncology (ESMO) 2019 Congress –

Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that initial data were presented from the single arm phase 2 clinical trial known as MOUNTAINEER. The trial is evaluating the investigational agent tucatinib in combination with trastuzumab (Herceptin^®) in patients with HER2-positive (HER2+), RAS wild-type metastatic colorectal cancer (mCRC) after treatment with first- and second-line standard-of-care therapies. The regimen demonstrated encouraging antitumor activity and was well tolerated.

Tucatinib is an oral, small molecule tyrosine kinase inhibitor that is highly selective for HER2. HER2 amplification or overexpression occurs in approximately three-to-five percent of all patients with mCRC.^1,2 The results were presented during a poster discussion session today at the European Society for Medical Oncology (ESMO) 2019 Congress in Barcelona, Spain (Abstract #527PD).

https://www.marketscreener.com/SEATTLE-GENETICS-INC-10808/news/Seattle-Genetics-Initial-Results-from-MOUNTAINEER-Trial-Show-Antitumor-Activity-of-Tucatinib-Combi-29274927/